From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Last Updated: Wednesday, June 26, 2024

Researchers performed a retrospective observational analysis of 2626 patients who underwent ASCT between 2017 and 2020 to clarify the prognostic impact of daratumumab before ASCT. The progression-free survival (PFS) rates and overall survival (OS) rates of the patients who could only achieve partial response or stable disease to progressive disease before ASCT in the patients who received daratumumab were significantly inferior to those of the patients in the group who didn’t receive it. However, in the patients who could obtain complete response or very good partial response with daratumumab treatment before ASCT, both the PFS and OS were significantly improved. 

Cancer Science
Advertisement
News & Literature Highlights

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Advertisement
Advertisement